08:38 AM EDT, 07/01/2024 (MT Newswires) -- Verrica Pharmaceuticals ( VRCA ) said Monday that it has settled litigation under which Canadian drugmaker Dormer Laboratories has agreed to stop selling all products containing cantharidin in the US, including Dormer's Cantharone and Cantharone Plus.

In February, Verrica filed a lawsuit against Dormer Laboratories to stop promoting and selling drugs containing cantharidin in the US. The company alleged that Dormer violated federal and state law through deceptive advertising and promotion of unapproved cantharidin-containing drugs, the company said.

"We are pleased to announce the expeditious settlement with Dormer Labs, which Verrica believes was the largest supplier of non-FDA approved cantharidin-containing products into the U.S. market," Verrica President and Chief Executive Ted White said in a statement. "Verrica will remain vigilant in its efforts to identify and stop any drug manufacturer or distributor that seeks to market, sell or distribute non-FDA approved cantharidin in the United States."

Dormer Laboratories did not immediately respond to a request for comment from MT Newswires.